i-jacoblogan-blog

[i-jacoblogan-blog]

US technology company Microsoft has launched its new retail solution to enhance the online and offline shopping experience for consumers. The Microsoft Synchronized Shopping solution makes use of ‘intelligent Cloud technology’ and has been developed in partnership with its Gold partner Popcornapps.

[i-jacoblogan-blog]

Cancer Research UK has announced a £56m research network to transform the UK into a global hub for radiotherapy study. By leveraging the use of the latest techniques, such as FLASH radiotherapy and artificial intelligence (AI), the network aims to accelerate the development of advanced radiotherapy.

[i-jacoblogan-blog]

Oil prices have slightly edged higher on China’s factory data but are on track for a weekly loss.Brent crude futures were down $0.27 at $59.89 a barrel, while US West Texas Intermediate (WTI) crude futures were down $0.32 at $54.50 per barrel, reported Reuters.

[i-jacoblogan-blog]

North American travel retailer Hudson Group has agreed to purchase a controlling stake in beverage concessions operator OHM Concession Group’s (OHM) assets.

[i-jacoblogan-blog]

Researchers from the Abramson Cancer Center of the University of Pennsylvania have found that liquid biopsy can help to predict the prognosis of glioblastoma(GBM), the most aggressive and common brain cancer in adults.

[i-jacoblogan-blog]

British retailer Marks & Spencer (M&S) has unveiled plans to launch an instalment payments facility online for its UK customers. On M&S.com, customers will now be able to pay interest-free within six weeks of purchasing M&S clothing and home products.

[i-jacoblogan-blog]

MedRhythms, a US-based digital therapeutics company, has launched its five-site randomised controlled trial (RCT) at rehabilitation hospitals and research centres to examine a post-stroke walking rehabilitation device.

[i-jacoblogan-blog]

Immuno-Transcriptomics firm Novigenix has received positive results from its early colon cancer detection blood test at the European Society for Medical Oncology (ESMO) 2019.

[i-jacoblogan-blog]

Patients with advanced non-small cell lung cancer (NSCLC) may soon be offered a blood test to assess their treatment options, instead of having to provide a tumour sample for analysis.

[i-jacoblogan-blog]

Advances in cancer treatments, such as immunotherapies and precision medicines, have been associated with a corresponding rise in the cost of new and innovative medicines.

[i-jacoblogan-blog]

Despite advances in the renal cell carcinoma (RCC) therapy landscape, the majority of patients with RCC will eventually develop resistance to available therapies and the disease will progress through several stages, requiring further lines of treatment.

[i-jacoblogan-blog]

Digital health interventions (DHIs) are fast emerging as vital tools to promote personal health and provide essential services. DHIs can be accessed through mobile phones, tablets and computers, as well as serve as effective support systems to improve personal health.

[i-jacoblogan-blog]

A research team led by the University of Strathclyde in the UK has developed an artificial intelligence (AI)-based blood test for the diagnosis of brain cancer.

[i-jacoblogan-blog]

ImmunoGen has presented full data from the Phase III Forward I study of mirvetuximab soravtansine in ovarian cancer at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, saying that it failed to meet the primary endpoint of progression-free survival (PFS).

[i-jacoblogan-blog]

Novartis has said that Kisqali delivered superior overall survival (OS) in the Monaleesa-3 trial, demonstrating more life for postmenopausal human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients.

[i-jacoblogan-blog]

A regimen of neoadjuvant Keytruda and chemotherapy extended pathological complete response (pCR) rates by 13.6% compared to chemotherapy alone in patients with early triple-negative breast cancer (TNBC), according to findings from the Phase III Keynote-522 study presented at the ESMO Congress 2019.

[i-jacoblogan-blog]

A Phase 3 study comparing Samsung Bioepis’ SB8 with Avastin in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) demonstrated equivalent efficacy in terms of risk ratio of overall response rate (ORR).